Improving how gut bacteria predict cancer immunotherapy success

A two-tier model based on gut microbiota composition may help distinguish between responder and non-responder cancer patients to immune checkpoint inhibitors.

• The gut microbiota is increasingly recognized as a factor influencing responses to immune checkpoint inhibitors.
• Discriminating between responder and non-responder patients remains a challenge in clinical settings.
• The proposed model utilizes gut microbiota composition to categorize patients based on their likelihood of responding to treatment.
• Findings may provide new avenues for using gut microbiota as a biomarker in cancer therapy.

Simplified